EFFICACY AND SAFETY OF MIBEFRADIL W/ VERAPAMIL IN MILD TO MODERATE HYPERTENSION

米贝拉地尔联合维拉帕米治疗轻至中度高血压的疗效和安全性

• 批准号: 6119094
• 负责人: BRENT M EGAN
• 金额: $ 1.74万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6119094
• 关键词: calcium channel blockers; cardiovascular disorder chemotherapy; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; hypertension; vasodilators; verapamil

To evaluate the differences between treatment groups in: The change of mean trough sitting diastolic blood pressure (SDBP) after 8 weeks of active treatment. The change of mean trough sitting systolic blood pressure (SSBP) after 8 weeks of active treatment. The change of mean trough sitting diastolic blood pressure (SDBP) after 4 weeks of active treatment. The change of mean trough sitting systolic blood pressure (SSBP) after 4 weeks of active treatment. To describe the mormalization rate and the response rate for each treatment group. To describe safety of mibefredil with that of verapamil SR through monitoring of adverse events and heart rate.

评价治疗组之间的差异：活性治疗8周后平均坐位舒张压谷值（SDBP）的变化。 积极治疗8周后平均坐位收缩压谷值（SSBP）的变化。 积极治疗4周后平均坐位舒张压谷值（SDBP）的变化。 积极治疗4周后平均坐位收缩压谷值（SSBP）的变化。 描述每个治疗组的正常化率和缓解率。 通过监测不良事件和心率来描述米贝福地尔与维拉帕米缓释剂的安全性。